These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 14656048)

  • 1. Oncogenic receptor tyrosine kinase in leukemia.
    Mizuki M; Ueda S; Matsumura I; Ishiko J; Schwäble J; Serve H; Kanakura Y
    Cell Mol Biol (Noisy-le-grand); 2003 Sep; 49(6):907-22. PubMed ID: 14656048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.
    Masson K; Rönnstrand L
    Cell Signal; 2009 Dec; 21(12):1717-26. PubMed ID: 19540337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
    Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
    Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling.
    Torrent M; Rickert K; Pan BS; Sepp-Lorenzino L
    J Mol Graph Model; 2004 Oct; 23(2):153-65. PubMed ID: 15363457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.
    Matsumura I; Mizuki M; Kanakura Y
    Cancer Sci; 2008 Mar; 99(3):479-85. PubMed ID: 18177485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic receptors of class III receptor-type tyrosine kinases.
    Rosnet O; Birnbaum D
    Crit Rev Oncog; 1993; 4(6):595-613. PubMed ID: 7506935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Nov; 337(1):1-13. PubMed ID: 16129412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
    Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
    Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT-3: a new focus in the understanding of acute leukemia.
    Markovic A; MacKenzie KL; Lock RB
    Int J Biochem Cell Biol; 2005 Jun; 37(6):1168-72. PubMed ID: 15778081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
    Neben K; Schnittger S; Brors B; Tews B; Kokocinski F; Haferlach T; Müller J; Hahn M; Hiddemann W; Eils R; Lichter P; Schoch C
    Oncogene; 2005 Feb; 24(9):1580-8. PubMed ID: 15674343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis of PDGFRA and PDGFRB genes by rapid single-strand conformation polymorphism (SSCP) in patients with core-binding factor leukaemias with KIT or FLT3 mutation.
    Trojani A; Ripamonti CB; Penco S; Beghini A; Nadali G; Di Bona E; Viola A; Castagnola C; Colapietro P; Grillo G; Pezzetti L; Ravelli E; Patrosso MC; Marocchi A; Cuneo A; Ferrara F; Lazzarino M; Pizzolo G; Cairoli R; Morra E
    Anticancer Res; 2008; 28(5A):2745-51. PubMed ID: 19035305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
    Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases.
    Schmidt-Arras DE; Böhmer A; Markova B; Choudhary C; Serve H; Böhmer FD
    Mol Cell Biol; 2005 May; 25(9):3690-703. PubMed ID: 15831474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis.
    Koch S; Jacobi A; Ryser M; Ehninger G; Thiede C
    Cells Tissues Organs; 2008; 188(1-2):225-35. PubMed ID: 18303245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
    Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
    Spiekermann K; Hiddemann W; Schnittger S
    Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
    [No Abstract]   [Full Text] [Related]  

  • 20. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.
    Grand FH; Iqbal S; Zhang L; Russell NH; Chase A; Cross NC
    Exp Hematol; 2007 Nov; 35(11):1723-7. PubMed ID: 17764812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.